CAP DPCA

Información principal

  • Denominación comercial:
  • CAP DPCA 2 Solución para diálisis peritoneal
  • formulario farmacéutico:
  • Solución para diálisis peritoneal
  • Usar para:
  • Humanos
  • Tipo de medicina:
  • medicamento alopático

Documentos

  • para el público en general:
  • El prospecto de información de este producto no está disponible actualmente, puede enviar una petición a nuestro servicio al cliente y le notificaremos tan pronto como nos sea posible para conseguirlo.


    Solicitar el prospecto de información al público.

Localización

  • Disponible en:
  • CAP DPCA 2 Solución para diálisis peritoneal
    Cuba
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • CECMED - Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos - Cuba
  • Número de autorización:
  • m11044b05-capd
  • última actualización:
  • 10-05-2018

Ficha Técnica

RESUMEN DE LAS CARACTERÍSTICAS DEL PRODUCTO

Nombre del producto:

CAP/DPCA 2 Solución para diálisis peritoneal

Forma farmacéutica:

Solución para diálisis peritoneal

Fortaleza:

Presentación:

Bolsa de PVC o biofine con 2000, 2500, 5000 y 6 000 mL.

Titular del Registro Sanitario, país:

FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH, BAD

HOMBURG, ALEMANIA.

Fabricante, país:

FRESENIUS MEDICAL CARE ANDINA S.A.S., CUNDINAMARCA,

COLOMBIA.

Número de Registro Sanitario:

M-11-044-B05

Fecha de Inscripción:

12 de Abril del 2011

Composición:

Cada 100 mL contiene:

Dextrosa

2,3000 g

Cloruro de sodio 0,57860 g

Lactato de sodio

0,39250 g

Cloruro de calcio dihidratado

0,02570 g

Cloruro de magnesio hexahidratado

Plazo de validez:

24 meses

Condiciones de almacenamiento:

Almacenar de 4 a 30 ºC.

Indicaciones Terapéuticas:

Insuficiencia renal crónica terminal, manejada mediante diálisis peritoneal automatizada.

Contraindicaciones:

Deficiencia en potasio (hipokalemia). Ante la presencia de los síntomas clínicos siguientes

CAPD/DPCA

sólo

puede

usarse

después

evaluación

cuidadosa

riesgo

beneficio bajo criterio facultativo:

Peritonitis localizada, no asociada a diálisis peritoneal.

Perforación de víscera intraabdominal.

Gestación avanzada.

Tumores intraabdominales.

Heridas abdominales recientes.

Hernias.

Enfermedad pulmonar, especialmente neumonía.

Caquexia.

Elevación notable de los lípidos séricos. (Hiperlipidemia severa).

Cirugía múltiple previa con adherencias.

Enfermedades intestinales inflamatorias.

Sepsis abdominal por cirugía previa o enfermedad inflamatoria abdominal severa.

Precauciones:

Almacenar a temperaturas inferiores a 25°C. Utilizar sólo soluciones transparentes y con

envases intactos. Mantener fuera del alcance de los niños. Los envases de plástico pueden

dañarse durante el transporte desde la fabrica al centro de diálisis o en el hospital. Esto

puede ocasionar contaminación de la solución de diálisis por bacterias u hongos. Es

necesario efectuar un control visual de la bolsa de solución peritoneal antes de conectarla.

Debe prestarse especial atención al sellado, a las juntas y a los extremos de la bolsa. En

caso de duda, la bolsa debe ser desechada. Utilizar la solución para diálisis peritoneal

solamente si la bolsa y el sellado no están dañados.

Advertencias especiales y precauciones de uso:

La instilación y eliminación del líquido deberá realizarse de forma aséptica, para reducir al

máximo los riesgos de peritonitis. Controlar con especial atención el volumen y aspecto del

líquido eliminado. Si éste se presenta turbio, especialmente si va acompañado de dolores

abdominales y fiebre, se deberán investigar las causas e iniciar el respectivo tratamiento.

Repetidos ataques de peritonitis pueden reducir la eficacia de la membrana peritoneal en el

intercambio.

Debido al contenido en glucosa de la solución, puede incrementarse la concentración de

glucosa en la sangre especialmente durante episodios de peritonitis, incluso en pacientes no

diabéticos. Consecuentemente deben comprobarse regularmente los niveles de azúcar en la

sangre. En los pacientes diabéticos, la administración diaria de insulina debe adaptarse a la

carga adicional de glucosa. Debe controlarse regularmente además de los electrolitos, los

niveles de sodio, potasio, magnesio, calcio y fosfato así como el equilibrio ácido-base y la

concentración de proteína sérica. Se recomienda un control diario de peso corporal y del

balance entre los volúmenes de infusión y drenaje. La administración a largo plazo produce

cambios en la membrana peritoneal. En tratamientos prolongados se aconseja que el

paciente tome dieta de alto contenido proteico. En caso de aplicaciones muy frecuentes

puede producirse una excesiva eliminación de líquidos y consecuentemente un descenso de

la presión sanguínea. En pacientes bajo tratamiento con digitálicos existe riesgo de arritmias

por eliminación rápida de potasio.

Efectos indeseables:

No presenta.

Posología y modo de administración:

A juicio del facultativo.

administración

realiza

mediante

máquina,

como

diálisis

peritoneal

cíclica

intermitente o continua, se recomienda utilizar bolsas de gran volumen.

Para el seguimiento de la eficacia terapéutica, deben controlarse regularmente los niveles

de creatinina y urea.

Advertencia:

caso

aplicación

demasiado

frecuente

puede

provocarse

excesiva extracción de fluidos y como consecuencia una bajada de la presión sanguínea.

Para

contrarrestar

este

efecto,

recomienda

administración

soluciones

contengan sodio.

Vía de administración:

Administrar por vía intraperitoneal a través del catéter para diálisis peritoneal colocado

previamente, empleando máquina para diálisis peritoneal automatizada.

CAPD/DPCA 2 se utiliza, en función de la ultrafiltración necesaria y de la concentración

electrolítica del suero. Puede utilizarse una única solución de diálisis peritoneal o combinar

soluciones de diferentes concentraciones de glucosa.

Duración del tratamiento.

De acuerdo alas instrucciones del médico responsable, CAPD/DPCA 2 se utiliza como

tratamiento a largo plazo.

Interacciones con otros productos medicinales y otras formas de interacción:

Insulina y antibacterianos.

Importante: Pueden realizarse mezclas con otros medicamentos sólo después de comprobar

su compatibilidad.

Uso en embarazo y lactancia:

Embarazo: puede ser utilizado en situaciones de alto riesgo en ausencia de soporte de

hemodiálisis. Categoría de riesgo para el embarazo: no clasificado.

Lactancia materna: no se han realizado estudios que hayan evaluado su seguridad.

Efectos sobre la conducción de vehículos/ maquinarias:

No presenta.

Sobredosis:

Medidas generales.

Propiedades Farmacodinámicas:

Las soluciones para diálisis son soluciones de electrolitos formuladas en concentraciones

similares al fluido extracelular. La glucosa o dextrosa puede ser añadida como agente

osmótico. El lactato contribuye a la liberación de CO

en la solución. Estas preparaciones se

utilizan para corregir trastornos renales y eliminar sustancias tóxicas de la sangre, de

acuerdo a su selectividad en el intercambio de iones.

Aunque la diálisis peritoneal tiene un uso limitado en el tratamiento de intoxicación, en

algunos casos puede salvar la vida. La eficiencia de la diálisis depende del gradiente de

concentración del veneno entre la sangre y el líquido de diálisis.

La diálisis peritoneal se hace por introducción del líquido de diálisis en la cavidad peritoneal

mediante un carácter colocado a través de una pequeña incisión en la sección derecha de la

región mesogástrica. Llevado como baño hidromineral a la cavidad peritoneal, permite retirar

con la ayuda de la serosa peritoneal como membrana dializadora, sustancias tóxicas y

metabolitos del organismo, así como lograr un equilibrio hidromineral ácido-base en los

casos de insuficiencia renal aguda o crónica terminal y en el caso de intoxicación exógena..

Propiedades

Farmacocinéticas

(absorción,

distribución,

biotransformación,

eliminación):

No presenta.

Instrucciones de uso, manipulación y destrucción del remanente no utilizable del

producto:

No presenta.

Fecha de aprobación / revisión del texto: 31 de enero de 2016.

  • El prospecto de información de este producto no está disponible actualmente, puede enviar una petición a nuestro servicio al cliente y le notificaremos tan pronto como nos sea posible para conseguirlo.

    Solicitar el prospecto de información al público.



  • Los documentos en otros idiomas están disponibles aquí

17-11-2018

Nuevo biomaterial para reparar el tejido nervioso dañado tras un ictus

Nuevo biomaterial para reparar el tejido nervioso dañado tras un ictus

Un equipo de científicos del Centro de Tecnología Biomédica de la Universidad Politécnica de Madrid (UPM), en colaboración con la Universidad Complutense de Madrid (UCM), el Instituto Cajal y el Hospital Clínico San Carlos, ha desarrollado un tratamiento novedoso para reparar tejido cerebral dañado. Gracias a la implantación de células madre encapsuladas en un biomaterial […]

Cuba - infomed - Red de Salud de Cuba

17-11-2018

The Quaker Oats Company Issues Voluntary Recall of a Small Quantity of Cap’n Crunch’s Peanut Butter Crunch Cereal Distributed to Five Target Stores Due to Possible Health Risk

The Quaker Oats Company Issues Voluntary Recall of a Small Quantity of Cap’n Crunch’s Peanut Butter Crunch Cereal Distributed to Five Target Stores Due to Possible Health Risk

The Quaker Oats Company, a subsidiary of PepsiCo, Inc., today announced a voluntary recall of a small quantity of Cap’n Crunch’s Peanut Butter Crunch cereal due to the potential presence of Salmonella. While the potentially affected product only reached five specific Target stores and is limited to 21 boxes of one variety with two Best Before Dates, Quaker is initiating the voluntary recall to protect public health.

FDA - U.S. Food and Drug Administration

14-11-2018

Several children's strawberry-flavoured acetaminophen syrups recalled because of defective child-resistant safety caps on the bottles

Several children's strawberry-flavoured acetaminophen syrups recalled because of defective child-resistant safety caps on the bottles

Laboratoire RivaInc. and Laboratoires Trianon Inc. are voluntarily recalling several over-the-counter children’s strawberry-flavoured acetaminophen syrups labeled as Biomedic, Option, or Laboratoires Trianon Inc. The products, which are used for pain and fever relief, are being recalled because the child-resistant safety cap may be defective.

Health Canada

14-11-2018

“Vita-X Revitalizing Capsules” for men may pose serious health risks

“Vita-X Revitalizing Capsules” for men may pose serious health risks

Health Canada is advising Canadians that two versions of “Vita-X Revitalizing Capsules” by Lanlay Healthmetic Inc., promoted for “long lasting vital energy for men,” may pose serious health risks. One version contains seven capsules and has “NPN 80053009,” a Natural Product Number (NPN) indicating Health Canada authorization, on the label. The second version contains one capsule, has no NPN on the label and is not authorized by Health Canada.

Health Canada

7-11-2018

Regionale top X- aanpak voor personen met verward gedrag

Regionale top X- aanpak voor personen met verward gedrag

Een aantal zorg- en veiligheidshuizen ontwikkelt een intensieve persoonsgerichte aanpak om in de regio personen met verward gedrag – de top X - beter in beeld te krijgen. Er zijn personen met een psychiatrische aandoening, die in verschillende mate agressief, ontwrichtend en gevaarlijk gedrag vertonen. Een specifieke groep lijkt verantwoordelijk voor een belangrijk deel van de overlast en risicovolle situaties. Deze groep vraagt extra aandacht van alle partijen: de politie, openbaar ministerie (OM), zorg...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

16-10-2018

Assessment of low pathogenic avian influenza virus transmission via raw poultry meat and raw table eggs

Assessment of low pathogenic avian influenza virus transmission via raw poultry meat and raw table eggs

Published on: Mon, 15 Oct 2018 00:00:00 +0200 A rapid qualitative assessment has been done by performing a theoretical analysis on the transmission of low pathogenic avian influenza (LPAI) via fresh meat from poultry reared or kept in captivity for the production of meat (raw poultry meat) or raw table eggs. A predetermined transmission pathway followed a number of steps from a commercial or non‐commercial poultry establishment within the EU exposed to LPAI virus (LPAIV) to the onward virus transmission...

Europe - EFSA - European Food Safety Authority Publications

16-10-2018

Fat Burners Zone Issues Voluntary Nationwide Recall of Zero Xtreme Due to Presence of Undeclared Sibutramine

Fat Burners Zone Issues Voluntary Nationwide Recall of Zero Xtreme Due to Presence of Undeclared Sibutramine

Fat Burners Zone is voluntarily recalling 1 lot of Zero Xtreme, capsules to the consumer level. FDA analysis has found Zero Xtreme to be tainted with sibutramine. Sibutramine is an appetite suppressant that was withdrawn from the U.S. market due to safety concerns. The presence of Sibutramine in Zero Xtreme renders it an unapproved drug for which safety and efficacy has not been established and, therefore, subject to recall.

FDA - U.S. Food and Drug Administration

9-10-2018

Europa: recomiendan restricciones al uso de las fluoroquinolonas y quinolonas

El Comité de Farmacovigilancia de la agencia europea propone nuevas restricciones luego de revisar los efectos secundarios discapacitantes y potencialmente duraderos. EMA, 5 de octubre de 2018

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

1-10-2018

Public Notification: Baschi Quick Slimming Capsule contains hidden drug ingredients

Public Notification: Baschi Quick Slimming Capsule contains hidden drug ingredients

The Food and Drug Administration is advising consumers not to purchase or use Baschi Quick Slimming Capsule, a product promoted for weight loss. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

1-10-2018

Public Notification: Green Lean Body Capsule contains hidden drug ingredients

Public Notification: Green Lean Body Capsule contains hidden drug ingredients

The Food and Drug Administration is advising consumers not to purchase or use Green Lean Body Capsule, a product promoted for weight loss. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

1-10-2018

Kabinet zet in op betere gehandicaptenzorg

Kabinet zet in op betere gehandicaptenzorg

Minister De Jonge (Volksgezondheid, Welzijn en Sport) komt op de eerste dag van de week van de toegankelijkheid met een reeks maatregelen om de zorg voor mensen met een beperking te verbeteren.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

27-9-2018

Oscor Inc. Issues Recall of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

Oscor Inc. Issues Recall of TB – Temporary Bipolar Pacing Lead (Unshrouded 2 mm Pins Models)

During the use of some TB - Temporary Bipolar Pacing Leads, featuring the 2mm unshrouded connectors, the connector cap housing (see Picture 1, No. 2 Pin Cap and Cover) may slide and potentially expose the connection wire. In some instances, this may cause the wire to be more susceptible to loss of connectivity or breakage during movement of the cables causing interruption of the pacing system. The analysis of the returned devices attributed the failure to a design change of the cap housing of the pins. ...

FDA - U.S. Food and Drug Administration

31-8-2018

Public Notification: Slimming Capsule contains hidden drug ingredients

Public Notification: Slimming Capsule contains hidden drug ingredients

The Food and Drug Administration is advising consumers not to purchase or use Slimming Capsule, a product promoted for weight loss. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

22-8-2018

Rhino 8 Platinum 8000 capsules

Rhino 8 Platinum 8000 capsules

Rhino 8 Platinum 8000 capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

16-8-2018

Zakah Life Recalls Kratom Because Of Possible Health Risk

Zakah Life Recalls Kratom Because Of Possible Health Risk

Zakah Life, LLC of Ankeny, Iowa, is recalling the following Kratom products (Super Green Maeng Da Premium Kratom powder, Powerful Red Vein Bali Premium Kratom powder, Super Green Maeng Da Premium Kratom capsules, and Powerful Red Vein Bali Premium Kratom capsules) with expiration dates prior to 01/01/2023 because they have the potential of being contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weak...

FDA - U.S. Food and Drug Administration

14-8-2018

Koehler-Bright Star recalls WorkSafe 3-D cell flashlights

Koehler-Bright Star recalls WorkSafe 3-D cell flashlights

The flashlights are missing an encapsulation on the circuit board component which could allow the flashlight to ignite in an explosive environment, posing a burn hazard and risk of personal injury to the user or bystander.

Health Canada

14-8-2018

World Organix, LLC Issues Voluntary Nationwide Recall of Blissful Remedies Red Maeng Da 100% Mitragyna Speciosa, Blissful Remedies Red Maeng Da Liquid Kratom Mitragyna Speciosa, Blissful Remedies 4 Hour Chill Slow Motion Blend, Due to High Microbial Loads

World Organix, LLC Issues Voluntary Nationwide Recall of Blissful Remedies Red Maeng Da 100% Mitragyna Speciosa, Blissful Remedies Red Maeng Da Liquid Kratom Mitragyna Speciosa, Blissful Remedies 4 Hour Chill Slow Motion Blend, Due to High Microbial Loads

World Organix LLC, is voluntarily recalling lot: 112710 of Blissful Remedies Red Maeng Da 100% Mitragyna Speciosa capsules, Blissful Remedies Red Maeng Da Liquid Kratom Mitragyna Speciosa, Blissful Remedies 4 Hour Chill Slow Motion Blend to the consumer level. These products have been tested by the U.S. Food and Drug Administration (“FDA”) and found to be contaminated with High Microbial Loads. Additionally, this serves as a update to a previous press release posted on June 30th 2018, concerning Blissful...

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Vismodegib hard capsule 150 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Vismodegib hard capsule 150 mg product-specific bioequivalence guidance, adopted

Vismodegib hard capsule 150 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

2-8-2018

Fairy capsules

Fairy capsules

Fairy capsules pose a serious risk to your health and should not be taken.

Therapeutic Goods Administration - Australia

23-7-2018

Flowers Foods Issues Voluntary Recall on Mrs. Freshley’s and Other Brands of Swiss Rolls and Captain John Derst’s Old Fashioned Bread

Flowers Foods Issues Voluntary Recall on Mrs. Freshley’s and Other Brands of Swiss Rolls and Captain John Derst’s Old Fashioned Bread

As a precautionary measure, Flowers Foods, Inc. (NYSE: FLO) is voluntarily recalling Swiss Rolls sold under the brand names Mrs. Freshley’s, Food Lion, H-E-B, Baker’s Treat, Market Square, and Great Value, distributed nationwide, and Captain John Derst’s Old Fashioned Bread distributed in Alabama, Florida, Georgia, North Carolina, and South Carolina, due to the potential presence of Salmonella in an ingredient, whey powder. The ingredient recall was initiated by a third-party whey powder manufacturer and...

FDA - U.S. Food and Drug Administration

9-7-2018

Public Notification: Grakcu Capsule contains hidden drug ingredients

Public Notification: Grakcu Capsule contains hidden drug ingredients

The Food and Drug Administration is advising consumers not to purchase or use Grakcu Capsule, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

6-7-2018

Buy Buy Baby recalls Ellen Degeneres Coveralls with Cap

Buy Buy Baby recalls Ellen Degeneres Coveralls with Cap

The coverall has a bunny applique which can detach and poses a choking hazard.

Health Canada

2-7-2018

Blissful Remedies Issues Voluntary Nationwide Recall of Certain Kratom Powder Capsule

Blissful Remedies Issues Voluntary Nationwide Recall of Certain Kratom Powder Capsule

Blissful Remedies., is voluntarily recalling only Lot No.: 112710 with expiration 03/2019 found embedded on the top of package of kratom ( mitragyn a speciosa) powder products, it manufactured, processed, packed, and/or held, between “March 1, 2018” to “April 30, 2018” to the consumer level. The products have been found by the U.S. Food and Drug Administration (“FDA”) via sample testing to have salmonella contamination. Blissful Remedies has not received reports of adverse events related to this recall. ...

FDA - U.S. Food and Drug Administration

19-6-2018

Platinum - Male Enhancer capsules

Platinum - Male Enhancer capsules

Platinum - Male Enhancer capsules pose a serious risk to your health and should not be taken.

Therapeutic Goods Administration - Australia

7-6-2018

Ovejoterapia: la nueva metodología que impacta física y cognitivamente en personas con discapacidad

Ovejoterapia: la nueva metodología que impacta física y cognitivamente en personas con discapacidad

“Las ovejas son una especie altamente social, superinteligentes, y son animales muy poco agresivos, por eso considerábamos que cumplían con requisitos mínimos para trabajar con niños en terapia, fue así como se nos ocurrió incluirlas en el trabajo terapéutico”, relata María José Ubilla, veterinaria, etóloga y coordinadora del Centro de Terapia Asistidas con Animales (CTAA) […]

Cuba - infomed - Red de Salud de Cuba

4-6-2018

Tabaco, déficit de vitamina D y dieta, posibles factores del aumento de esclerosis múltiple en España

Tabaco, déficit de vitamina D y dieta, posibles factores del aumento de esclerosis múltiple en España

Según datos de la Sociedad Española de Neurología (SEN), la esclerosis múltiple (EM) afecta a 47 000 personas en España y es, tras los accidentes de tráfico, la principal causa de discapacidad en jóvenes. Cada año se diagnostican 1800 nuevos casos en España de esta enfermedad, que afecta a 700 000 personas en Europa y […]

Cuba - infomed - Red de Salud de Cuba

2-6-2018

Solve Botanical Slimming capsules

Solve Botanical Slimming capsules

Safety advisory - Solve Botanical Slimming capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

29-5-2018

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. As a result of this packaging error, oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy. The reversing of the order may not be apparent to either new users or previous ...

FDA - U.S. Food and Drug Administration

29-5-2018

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal...

FDA - U.S. Food and Drug Administration

23-5-2018

Hypnotic poisom capsules

Hypnotic poisom capsules

Hypnotic poisom capsules safety advisory

Therapeutic Goods Administration - Australia

18-5-2018

MindFrame Capture LP Revascularization Device by Medtronic: Class I Recall - Due to Wire Material That May Break or Separate During Use

MindFrame Capture LP Revascularization Device by Medtronic: Class I Recall - Due to Wire Material That May Break or Separate During Use

There is a risk of the delivery wire breaking or separating during use. The clot retriever could be left inside the patient's bloodstream, and this or the attempts made to retrieve the device, can lead to further complications including bleeding, additional blockage of blood vessels, more severe stroke symptoms, or death.

FDA - U.S. Food and Drug Administration

17-5-2018

JAGUAR 30000 capsules

JAGUAR 30000 capsules

Safety advisory

Therapeutic Goods Administration - Australia

14-5-2018

Lishou Strong Slimming capsule

Lishou Strong Slimming capsule

Safety advisory

Therapeutic Goods Administration - Australia

9-5-2018

SLIM BODY Advanced capsules

SLIM BODY Advanced capsules

Safety advisory

Therapeutic Goods Administration - Australia

4-5-2018

Maya Distribution, LLC Recalls Dragon Label Kratom Because Of Possible Salmonella Contamination

Maya Distribution, LLC Recalls Dragon Label Kratom Because Of Possible Salmonella Contamination

Maya Distribution, LLC of South Salt Lake City, Utah is voluntarily recalling Dragon Kratom labeled bottles and sealed packages of encapsulated and raw powder product because it has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. 

FDA - U.S. Food and Drug Administration

30-4-2018

Foreign Product Alert: 7 Days Slim hip & Legs caps, CA NI CAP Arm Slim, Perfect Slim by Peenuch capsules, Slim Perfect Legs, Ure Tonic Herbal Traditional

Foreign Product Alert: 7 Days Slim hip & Legs caps, CA NI CAP Arm Slim, Perfect Slim by Peenuch capsules, Slim Perfect Legs, Ure Tonic Herbal Traditional

These foreign health products have been found by regulators in other countries to contain undeclared drug ingredients.

Health Canada

19-4-2018

NxtGen Botanicals Maeng Da Kratom by NGB Corp.: Recall - Possible Salmonella Contamination

NxtGen Botanicals Maeng Da Kratom by NGB Corp.: Recall - Possible Salmonella Contamination

NGB Corp. of West Jordan, Utah is voluntarily recalling NxtGen Botanicals Maeng Da Kratom labeled bottles of encapsulated product because it has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infec...

FDA - U.S. Food and Drug Administration

18-4-2018

ViaGro 500mg Male Enhancement capsules

ViaGro 500mg Male Enhancement capsules

Safety advisory

Therapeutic Goods Administration - Australia

17-4-2018

Gold Viagra 9800mg capsules

Gold Viagra 9800mg capsules

Safety advisory

Therapeutic Goods Administration - Australia

17-4-2018

LIPRO Dietary capsules

LIPRO Dietary capsules

Safety advisory

Therapeutic Goods Administration - Australia

17-4-2018

Epic Products, LLC, Issues Voluntary Nationwide Recall of All Lots of Euphoric Capsules Due to Presence of Undeclared Sildenafil and Tadalafil

Epic Products, LLC, Issues Voluntary Nationwide Recall of All Lots of Euphoric Capsules Due to Presence of Undeclared Sildenafil and Tadalafil

Overland Park, KS, Epic Products, LLC is voluntarily recalling all lots of Euphoric capsules, packaged in 1 count blister cards, 3 count bottles, and 12 count bottles to the consumer level. FDA analysis found samples of Euphoric to be tainted with undeclared sildenafil and tadalafil, active ingredients in two FDA-approved prescription drug products, also known as phosphodiesterase 5-inhibitors (PDE-5 inhibitors), used to treat male erectile dysfunction (ED). The presence of sildenafil and tadalafil in E...

FDA - U.S. Food and Drug Administration

14-4-2018

'Rhino 69 Extreme 50000' Recalled due to Presence of Active Ingredient 'Tadalafil'

'Rhino 69 Extreme 50000' Recalled due to Presence of Active Ingredient 'Tadalafil'

AMA Wholesale Inc. (Distributor/Re-seller), is voluntarily recalling Rhino 69 Extreme 50000 capsules to the consumer level. FDA analysis found the product to be tainted with undeclared tadalafil. Tadalafil is an active ingredient in a FDA-approved prescription drug that is used for erectile dysfunction.

FDA - U.S. Food and Drug Administration

9-4-2018

Vegetal Vigra capsules

Vegetal Vigra capsules

Safety advisory

Therapeutic Goods Administration - Australia

27-3-2018

Slim Trim Gold capsules

Slim Trim Gold capsules

Slim Trim Gold capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

27-3-2018

Lida (Plus) capsules

Lida (Plus) capsules

Lida (Plus) capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

20-3-2018

Nutra Organics Green Tea Extract capsules

Nutra Organics Green Tea Extract capsules

Safety alert- Nutra Organics Green Tea Extract capsules

Therapeutic Goods Administration - Australia

19-3-2018

Arthrem capsules

Arthrem capsules

Safety advisory – potential risk of harm to the liver

Therapeutic Goods Administration - Australia

7-3-2018

Ja Dera Max+ capsules

Ja Dera Max+ capsules

Ja Dera Max+ capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

28-2-2018

Help 100% & Pure Natural & Body Slim capsules

Help 100% & Pure Natural & Body Slim capsules

Help 100% & Pure Natural & Body Slim Capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

23-2-2018

Bella all Natural Issues Voluntary Nationwide Recall of Diet Capsules Labeled as Bella, Due to Presence of Sibutramine

Bella all Natural Issues Voluntary Nationwide Recall of Diet Capsules Labeled as Bella, Due to Presence of Sibutramine

Bella All Natural is voluntarily recalling its Diet Capsules labeled as Bella, Lot Number MFD:10.15.2017 EXP: 10.14.2019, to the consumer level.

FDA - U.S. Food and Drug Administration

6-2-2018

Perfect slim capsules by Peenuch

Perfect slim capsules by Peenuch

Perfect slim capsules contain the undeclared substance sibutramine.

Therapeutic Goods Administration - Australia

16-1-2018

Yunnan Feng Shi Ling capsules – counterfeit

Yunnan Feng Shi Ling capsules – counterfeit

Yunnan Feng Shi Ling capsules contain the undeclared substance paracetamol.

Therapeutic Goods Administration - Australia

19-12-2017

Counterfeit: SLAM Natural Formula 29000 mg capsules

Counterfeit: SLAM Natural Formula 29000 mg capsules

SLAM Natural Formula 29000 mg capsules pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

11-12-2017

Semenax capsules (counterfeit version)

Semenax capsules (counterfeit version)

Safety Alert- Semenax capsules (counterfeit version)

Therapeutic Goods Administration - Australia

10-7-2018

Corbilta (Orion Corporation)

Corbilta (Orion Corporation)

Corbilta (Active substance: levodopa / carbidopa / entacapone) - Centralised - Renewal - Commission Decision (2018)4468 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2785/R/15

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2025 (Pharma Gateway AB)

EU/3/18/2025 (Pharma Gateway AB)

EU/3/18/2025 (Active substance: Modified mRNA encoding human methylmalonyl-coenzyme A mutase encapsulated into lipid nanoparticles) - Orphan designation - Commission Decision (2018)3393 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/017/18

Europe -DG Health and Food Safety

6-4-2018

EU/3/12/1072 (Le4D Limited)

EU/3/12/1072 (Le4D Limited)

EU/3/12/1072 (Active substance: Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor) - Transfer of orphan designation - Commission Decision (2018)2008 of Fri, 06 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/160/11/T/01

Europe -DG Health and Food Safety